Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: A phase I study

H. Ueoka, Masahiro Tabata, Katsuyuki Kiura, T. Shibayama, K. Gemba, Y. Segawa, K. Chikamori, T. Yonei, S. Hiraki, M. Harada

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m-2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m-2, and the dose was escalated by an increase of 10 mg m-2. The maximally tolerated dose of CPT-11 was determined as 60 mg m-2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m-2 and 60 mg m-2 respectively.

Original languageEnglish
Pages (from-to)984-990
Number of pages7
JournalBritish Journal of Cancer
Volume79
Issue number5-6
DOIs
Publication statusPublished - 1999

Fingerprint

irinotecan
Cisplatin
Lung Neoplasms
Therapeutics
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Diarrhea
Maximum Tolerated Dose
Leukopenia

Keywords

  • Cisplatin
  • Irinotecan
  • Non-small-cell lung cancer
  • Phase I study
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer : A phase I study. / Ueoka, H.; Tabata, Masahiro; Kiura, Katsuyuki; Shibayama, T.; Gemba, K.; Segawa, Y.; Chikamori, K.; Yonei, T.; Hiraki, S.; Harada, M.

In: British Journal of Cancer, Vol. 79, No. 5-6, 1999, p. 984-990.

Research output: Contribution to journalArticle

Ueoka, H, Tabata, M, Kiura, K, Shibayama, T, Gemba, K, Segawa, Y, Chikamori, K, Yonei, T, Hiraki, S & Harada, M 1999, 'Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: A phase I study', British Journal of Cancer, vol. 79, no. 5-6, pp. 984-990. https://doi.org/10.1038/sj.bjc.6690157
Ueoka, H. ; Tabata, Masahiro ; Kiura, Katsuyuki ; Shibayama, T. ; Gemba, K. ; Segawa, Y. ; Chikamori, K. ; Yonei, T. ; Hiraki, S. ; Harada, M. / Fractionated administration of irinotecan and cisplatin for treatment of lung cancer : A phase I study. In: British Journal of Cancer. 1999 ; Vol. 79, No. 5-6. pp. 984-990.
@article{0e04784a563a40b18ebbebff5a21c5e9,
title = "Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: A phase I study",
abstract = "A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m-2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m-2, and the dose was escalated by an increase of 10 mg m-2. The maximally tolerated dose of CPT-11 was determined as 60 mg m-2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76{\%} for NSCLC and 100{\%} for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m-2 and 60 mg m-2 respectively.",
keywords = "Cisplatin, Irinotecan, Non-small-cell lung cancer, Phase I study, Small-cell lung cancer",
author = "H. Ueoka and Masahiro Tabata and Katsuyuki Kiura and T. Shibayama and K. Gemba and Y. Segawa and K. Chikamori and T. Yonei and S. Hiraki and M. Harada",
year = "1999",
doi = "10.1038/sj.bjc.6690157",
language = "English",
volume = "79",
pages = "984--990",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5-6",

}

TY - JOUR

T1 - Fractionated administration of irinotecan and cisplatin for treatment of lung cancer

T2 - A phase I study

AU - Ueoka, H.

AU - Tabata, Masahiro

AU - Kiura, Katsuyuki

AU - Shibayama, T.

AU - Gemba, K.

AU - Segawa, Y.

AU - Chikamori, K.

AU - Yonei, T.

AU - Hiraki, S.

AU - Harada, M.

PY - 1999

Y1 - 1999

N2 - A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m-2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m-2, and the dose was escalated by an increase of 10 mg m-2. The maximally tolerated dose of CPT-11 was determined as 60 mg m-2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m-2 and 60 mg m-2 respectively.

AB - A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m-2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m-2, and the dose was escalated by an increase of 10 mg m-2. The maximally tolerated dose of CPT-11 was determined as 60 mg m-2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m-2 and 60 mg m-2 respectively.

KW - Cisplatin

KW - Irinotecan

KW - Non-small-cell lung cancer

KW - Phase I study

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0033063624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033063624&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6690157

DO - 10.1038/sj.bjc.6690157

M3 - Article

C2 - 10070901

AN - SCOPUS:0033063624

VL - 79

SP - 984

EP - 990

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5-6

ER -